Diagnosis and treatment of cystic fibrosis in India: What is at stake for developing countries?

Simple item page
dc.contributor.authorPURUSHOTHAMAN, ANAND KUMARen_US
dc.contributor.authorNATARAJAN, SRIKANTHen_US
dc.contributor.authorPANIGRAHI, TRAILOKYANATHen_US
dc.contributor.authorNELSON, EVERETTE JACOB REMINGTONen_US
dc.date.accessioned2024-11-30T11:24:43Z
dc.date.available2024-11-30T11:24:43Z
dc.date.issued2024-06
dc.description.abstractCystic fibrosis (CF) is a life-threatening monogenic disease affecting thousands of people worldwide. Cystic fibrosis transmembrane conductance regulator (CFTR) is an ion channel that facilitates transportation of water and salts across epithelial cell membranes through the conductance of Cl? and other anions. A dysfunctional CFTR due to abnormalities in the cftr gene causes CF, which is believed to be a rare disease in India mainly due to mis/underdiagnosis. Although numerous diagnostic methods and treatment options are available for CF globally, most of these are unaffordable for developing countries like India. Currently, CF symptoms are managed with mucolytics, antibiotics, anti-inflammatory drugs, and various CFTR modulators based on the type of defect. While a definitive cure for CF remains elusive, advancements in stem cell and gene therapies hold promise for permanent cure in the near future. In this review, we discuss the prevalence of CF cases in India, affordable diagnostic methods, and treatment options amenable for developing countries. We further emphasize the scope for the universal newborn screening programme.en_US
dc.identifier.affiliationsGene Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Indiaen_US
dc.identifier.affiliationsGene Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Indiaen_US
dc.identifier.affiliationsGene Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Indiaen_US
dc.identifier.affiliationsGene Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Indiaen_US
dc.identifier.citationPURUSHOTHAMAN ANAND KUMAR, NATARAJAN SRIKANTH, PANIGRAHI TRAILOKYANATH, NELSON EVERETTE JACOB REMINGTON. Diagnosis and treatment of cystic fibrosis in India: What is at stake for developing countries?. Journal of Biosciences. 2024 Jun; 49: 1-8en_US
dc.identifier.issn0250-5991
dc.identifier.issn0973-7138
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/237982
dc.languageenen_US
dc.publisherThe Indian Academy of Sciencesen_US
dc.relation.volume49en_US
dc.source.urihttps://doi.org/10.1007/s12038-024-00456-5en_US
dc.subjectCystic fibrosisen_US
dc.subjectCFTRen_US
dc.subjectdiagnostic methodsen_US
dc.subjectIndian CFen_US
dc.subjectnewborn screeningen_US
dc.subjecttreatment optionsen_US
dc.titleDiagnosis and treatment of cystic fibrosis in India: What is at stake for developing countries?en_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
jb2024v49p1ar.pdf
Size:
434.19 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Biosciences